CD274 and neoplasm: ICI prevent interaction of receptor and corresponding ligands such as CTLA-4/CD80/86, PD-1/PD-L1/2, PD-L1/2/CD80, and LAG-3/MHC-II, and thus override tumor’s survival mechanisms, especially the inhibition of T cell activity (Fig. 5) [18, 120].